NICE has published its final appraisal document on niraparib for maintenance treatment of advanced ovarian, fallopian tube, and peritoneal cancer.
According to the draft guidance, niraparib will be available via the Cancer Drugs Fund (CDF) as an option for maintenance treatment of advanced (FIGO stages 3 and 4), high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer after a response to first-line, platinum-based chemotherapy in adults. The recommendation only applies if the conditions of the managed access agreement are met.
Owing to clinical uncertainty around the evidence for niraparib, NICE could not be certain that the drug’s cost-effectiveness would meet its criteria. However, while more data are collected from clinical trials, NICE will recommend niraparib for use through the CDF.